Lecanemab has given us more years together. That’s not ‘minute’ nor ‘minimal’ to me,” writes one reader in STAT’s letters to ...

Fraud, Arrogance, and Tragedy in the Quest to Cure Alzheimer’s,” Charles Piller looks how the amyloid hypothesis took over ...

More than 2 years since the original trial data for lecanemab in Alzheimer's disease was published,1 and over 1·5 years since approval by the US Food and Drug Administration, brain volume data have ...

在阿尔茨海默病（Alzheimer's disease，AD）的研究领域，一直存在着诸多谜团等待科学家们去解开。淀粉样蛋白 β（Amyloid-beta，Aβ）和 tau 蛋白的沉积，是 AD 的标志性病理特征 ，可这些病理变化往往在临床症状出现前许多年就已悄然开始。如今，针对 AD 的疾病修饰疗法，比如抗 Aβ 和抗 tau 抗体疗法不断涌现，这就使得在疾病的临床前期实现早期检测和精准预测 AD ...

Alzheimer’s disease — which affects an estimated 7 million Americans — is notoriously difficult to detect, especially in its ...

The factor that tips you over the edge from being at risk for a disease to actually developing the disease is not always ...

Researchers from Osaka University find that peristaltic pump action and high shear flow forces promote amyloid nucleation.

Researchers from Osaka University found that peristaltic pump flow mechanically breaks supersaturation to induce amyloid ...

为解决抗淀粉样治疗难题，俄罗斯科学院细胞学研究所研究人员开展 CTSB 对多种疾病相关淀粉样纤维影响的研究。结果发现 CTSB 能降解纤维并降低毒性。该研究为理解疾病机制和开发新疗法提供依据，值得科研人员一读。 俄罗斯科学院细胞学研究所（Institute of Cytology Russian Academy of Sciences）的研究人员 Maksim I. Sulatsky、Olesya ...

Alzheimer's patients with a baseline CDR-SB score of 3.5 could expect approximately 4 additional months (95% CI 2-7 months) ...